Although the approach that the pharmaceutical company has implemented for the vaccine goes hand in hand with the strategies of the different governments, including that of Mexico,
While the pharmaceutical company took on the project with the promise of not making a profit during the most critical stage of the coronavirus pandemic in the second quarter of 2020, the sale of the antidote has already given a boost to its global revenue this year. AstraZeneca had a turnover of 7.32 billion dollars in the first quarter of 2021, an increase of 11% compared to the same period of the previous year. Without the income from the vaccine, the increase is 7%, according to the financial statement of the company.
Varela said that the pharmaceutical company is also working on the development of treatments to prevent and treat coronavirus patients, based on monoclonal antibodies: proteins created in laboratories that mimic the function of the immune system to attack a specific virus.
The use of monoclonal antibodies has been evaluated since December last year in the United States, when the Food and Drug Administration (FDA) approved the emergency use of Bamlanivimab and Etesevimab to treat certain cases of COVID-19. In Mexico, the Federal Commission for the Protection of Sanitary Risks (Cofepris) is preparing the approval for this combination of antibodies for patients over 12 years of age at risk of presenting a serious picture of the disease.
The company conducted clinical studies in more than 900 patients globally, of which 305 are in Mexico. The results of these evaluations will be ready by the end of this year and if successful, the drugs will see the light of day next year. “We are absolutely believers in the relevance of vaccination to achieve important results in the fight against Covid, which, complemented with this other type of newer and high-tech drugs, will allow to control the level of infections,” he says.
The coronavirus vaccine market will reach a value of $ 13.6 billion at the end of this year, rising to $ 19.5 billion in 2026, with a compound annual growth rate (the rate that measures return on investment) of 7.6% in case annual vaccination is required, projects the GlobalData consultancy.
AstraZeneca does not have a market share target at this time. “Right now our focus is not the private market. We do not rule out that in the future there will be a change within the company’s objectives and that we will move towards a potentially commercial approach. But that is a decision that we have not made and it remains to be seen in the future ”, he says.